PUBLISHER: Acute Market Reports | PRODUCT CODE: 1383565
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1383565
Lung Cancer Diagnostics Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
The lung cancer diagnostics market is pivotal in the early detection and management of lung cancer, a deadly disease with high mortality rates. The lung cancer diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period of 2023 to 2031. The lung cancer diagnostics market plays a critical role in addressing the rising prevalence of lung cancer globally. Key drivers include the increasing burden of lung cancer, technological advancements, and the shift toward personalized medicine. Despite challenges related to costs, the market is poised for growth, with lung tissue analysis and small-cell lung cancer diagnostics expected to lead in terms of CAGR. The Asia-Pacific region is anticipated to be a significant growth driver. Leading companies are focusing on innovation, partnerships, global expansion, and patient-centered approaches to maintain their competitive edge in this dynamic market.
Rising Prevalence and Mortality of Lung Cancer
The foremost driver of the lung cancer diagnostics market is the alarming rise in the prevalence and mortality of lung cancer worldwide. Lung cancer remains one of the leading causes of cancer-related deaths, with an increasing incidence, particularly among smokers and individuals exposed to environmental carcinogens. Evidence of this can be observed in global cancer statistics, which consistently highlight lung cancer's significant burden on healthcare systems. The urgent need for early detection and timely intervention drives demand for advanced diagnostic tests.
Technological Advancements in Diagnostic Imaging
Advances in diagnostic imaging technologies, such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), have revolutionized lung cancer diagnostics. These technologies allow for the early detection of tumors, accurate staging, and monitoring of treatment response. Evidence of this progress can be seen in the increasing adoption of 3D imaging techniques and artificial intelligence (AI) algorithms for image analysis, which enhance the sensitivity and specificity of lung cancer diagnostics.
Growing Emphasis on Personalized Medicine
The growing emphasis on personalized medicine and targeted therapies is another key driver. Lung cancer is not a single disease; it encompasses various subtypes, with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) being the most common. Advances in molecular diagnostics have enabled the identification of specific genetic mutations and biomarkers associated with different lung cancer subtypes. Evidence of this trend can be found in the increasing use of genetic testing and liquid biopsy techniques to guide treatment decisions and optimize therapeutic outcomes, which fosters growth in the lung cancer diagnostics market.
Restraint of the Lung Cancer Diagnostics Market
While the lung cancer diagnostics market is poised for growth, a significant restraint is the challenges associated with the high cost of advanced diagnostic tests and treatments. Evidence of this restraint can be observed in the financial burden on healthcare systems and patients, particularly in low- and middle-income countries. Access to cutting-edge diagnostics and targeted therapies can be limited due to cost considerations, creating disparities in lung cancer care. Addressing this restraint requires innovative pricing models, healthcare financing strategies, and global collaboration to ensure equitable access to life-saving diagnostic tools and treatments.
Market Segmentation by Diagnostic Test Type (Imaging Tests, Pulmonary Function Tests, Lung Tissue Analysis, Others): Imaging Tests Dominate the Market
In 2022, the highest revenue within the lung cancer diagnostics market was generated by imaging tests, reflecting their widespread use for screening and diagnosis. However, during the forecast period from 2023 to 2031, lung tissue analysis is expected to exhibit the highest compound annual growth rate (CAGR). This growth is attributed to advancements in biopsy techniques, including minimally invasive procedures, and the increasing demand for molecular profiling to guide treatment decisions.A Market Segmentation by Cancer Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)): NSCLCDominates the Market
In 2022, NSCLC accounted for the highest revenue within the lung cancer diagnostics market, reflecting its higher prevalence compared to SCLC. However, during the forecast period from 2023 to 2031, SCLC is expected to experience the highest CAGR. This shift is driven by advancements in SCLC diagnostics and the development of targeted therapies for this aggressive cancer subtype.
North America Remains the Global Leader
Geographically, the lung cancer diagnostics market exhibits varying trends. North America has traditionally held a significant revenue share, primarily due to the early adoption of advanced diagnostic technologies and a high prevalence of lung cancer. However, the Asia-Pacific region is expected to demonstrate the highest CAGR during the forecast period. This growth is driven by factors such as a large population, rising awareness about lung cancer, and improving healthcare infrastructure. The region with the highest revenue percentage in 2022 was North America, reflecting its well-established healthcare systems. However, the Asia-Pacific region is expected to surpass North America in terms of CAGR. As governments and healthcare providers in the Asia-Pacific region prioritize cancer screening and early detection, the demand for lung cancer diagnostics is expected to surge.
Market Competition to Intensify during the Forecast Period
The lung cancer diagnostics market is highly competitive, with several key players striving to offer innovative solutions and maintain their market positions. Leading companies, including Roche Diagnostics, Thermo Fisher Scientific, bioMerieux, Qiagen N.V., Agilent Technologies, SanofiS.A. and Siemens Healthineers, employ various strategies to stay competitive in the market. Leading companies are heavily investing in research and development to introduce innovative diagnostic tools, including liquid biopsy tests, next-generation sequencing, and AI-driven diagnostic algorithms. These technologies enhance the accuracy and efficiency of lung cancer diagnostics. Companies are forming strategic partnerships and collaborations with research institutions, healthcare providers, and pharmaceutical companies to develop and commercialize new diagnostic solutions. Collaboration enables them to access complementary expertise and resources. Leading players are expanding their global presence through acquisitions and mergers, enabling them to broaden their product portfolios and reach new markets. This strategy also allows companies to diversify their revenue streams. Companies are adopting patient-centric approaches, emphasizing early detection, patient education, and personalized treatment options. This approach not only enhances patient outcomes but also strengthens brand reputation.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofLung Cancer Diagnostics market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Lung Cancer Diagnostics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Diagnostic Test Type
- Imaging Tests
- Pulmonary Function Tests
- Lung Tissue Analysis
- Others
Cancer Type
- Non-small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
End-User
- Hospitals
- Clinics
- Diagnostic Centers
Region Segment (2021-2031; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Lung Cancer Diagnostics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Lung Cancer Diagnostics market?
- Which is the largest regional market for Lung Cancer Diagnostics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Lung Cancer Diagnostics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Lung Cancer Diagnostics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Lung Cancer Diagnostics Market
- 2.2. Global Lung Cancer Diagnostics Market, By Diagnostic Test Type, 2022 (US$ Million)
- 2.3. Global Lung Cancer Diagnostics Market, By Cancer Type, 2022 (US$ Million)
- 2.4. Global Lung Cancer Diagnostics Market, By End-User, 2022 (US$ Million)
- 2.5. Global Lung Cancer Diagnostics Market, By Geography, 2022 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2022
3. Lung Cancer Diagnostics Market: Competitive Analysis
- 3.1. Market Positioning of Key Lung Cancer Diagnostics Market Vendors
- 3.2. Strategies Adopted by Lung Cancer Diagnostics Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2022 Versus 2031
4. Lung Cancer Diagnostics Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Lung Cancer Diagnostics Market Value, 2021 - 2031, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2022 Versus 2031
- 5.3. Market Segmentation
- 5.3.1. Imaging Tests
- 5.3.2. Pulmonary Function Tests
- 5.3.3. Lung Tissue Analysis
- 5.3.4. Others
6. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2022 Versus 2031
- 6.3. Market Segmentation
- 6.3.1. Non-small Cell Lung Cancer (NSCLC)
- 6.3.2. Small Cell Lung Cancer (SCLC)
7. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2022 Versus 2031
- 7.3. Market Segmentation
- 7.3.1. Hospitals
- 7.3.2. Clinics
- 7.3.3. Diagnostic Centers
8. North America Lung Cancer Diagnostics Market, 2021-2031, USD (Million)
- 8.1. Market Overview
- 8.2. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 8.3. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 8.4. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.Lung Cancer Diagnostics Market: By Region, 2021-2031, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 8.5.1.1.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 8.5.1.1.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 8.5.1.2.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 8.5.1.2.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 8.5.1.3.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 8.5.1.3.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1.North America
9. UK and European Union Lung Cancer Diagnostics Market, 2021-2031, USD (Million)
- 9.1. Market Overview
- 9.2. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.3. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.4. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.Lung Cancer Diagnostics Market: By Region, 2021-2031, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.1.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.1.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.2.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.2.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.3.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.3.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.4.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.4.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.5.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.5.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 9.5.1.6.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 9.5.1.6.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.1. UK
- 9.5.1.UK and European Union
10. Asia Pacific Lung Cancer Diagnostics Market, 2021-2031, USD (Million)
- 10.1. Market Overview
- 10.2. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.3. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.4. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.Lung Cancer Diagnostics Market: By Region, 2021-2031, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.1.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.1.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.2.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.2.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.3.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.3.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.4.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.4.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.5.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.5.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 10.5.1.6.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 10.5.1.6.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.1. China
- 10.5.1.Asia Pacific
11. Latin America Lung Cancer Diagnostics Market, 2021-2031, USD (Million)
- 11.1. Market Overview
- 11.2. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 11.3. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 11.4. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.Lung Cancer Diagnostics Market: By Region, 2021-2031, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 11.5.1.1.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 11.5.1.1.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 11.5.1.2.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 11.5.1.2.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 11.5.1.3.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 11.5.1.3.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1.Latin America
12. Middle East and Africa Lung Cancer Diagnostics Market, 2021-2031, USD (Million)
- 12.1. Market Overview
- 12.2. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 12.3. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 12.4. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.Lung Cancer Diagnostics Market: By Region, 2021-2031, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 12.5.1.1.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 12.5.1.1.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 12.5.1.2.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 12.5.1.2.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Lung Cancer Diagnostics Market: By Diagnostic Test Type, 2021-2031, USD (Million)
- 12.5.1.3.2. Lung Cancer Diagnostics Market: By Cancer Type, 2021-2031, USD (Million)
- 12.5.1.3.3. Lung Cancer Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.1. GCC
- 12.5.1.Middle East and Africa
13. Company Profile
- 13.1. Roche Diagnostics
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. Thermo Fisher Scientific
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. bioMerieux
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. Qiagen N.V.
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Agilent Technologies
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. SanofiS.A.
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Siemens Healthineers
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. Other Notable Players
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 2 Global Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 3 Global Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 4 North America Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 5 North America Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 6 North America Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 7 U.S. Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 8 U.S. Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 9 U.S. Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 10 Canada Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 11 Canada Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 12 Canada Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 13 Rest of North America Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 14 Rest of North America Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 15 Rest of North America Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 16 UK and European Union Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 17 UK and European Union Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 18 UK and European Union Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 19 UK Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 20 UK Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 21 UK Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 22 Germany Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 23 Germany Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 24 Germany Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 25 Spain Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 26 Spain Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 27 Spain Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 28 Italy Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 29 Italy Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 30 Italy Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 31 France Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 32 France Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 33 France Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 34 Rest of Europe Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 35 Rest of Europe Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 36 Rest of Europe Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 37 Asia Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 38 Asia Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 39 Asia Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 40 China Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 41 China Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 42 China Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 43 Japan Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 44 Japan Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 45 Japan Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 46 India Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 47 India Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 48 India Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 49 Australia Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 50 Australia Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 51 Australia Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 52 South Korea Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 53 South Korea Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 54 South Korea Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 55 Latin America Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 56 Latin America Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 57 Latin America Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 58 Brazil Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 59 Brazil Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 60 Brazil Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 61 Mexico Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 62 Mexico Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 63 Mexico Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 64 Rest of Latin America Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 65 Rest of Latin America Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 66 Rest of Latin America Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 67 Middle East and Africa Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 68 Middle East and Africa Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 69 Middle East and Africa Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 70 GCC Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 71 GCC Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 72 GCC Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 73 Africa Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 74 Africa Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 75 Africa Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 76 Rest of Middle East and Africa Lung Cancer Diagnostics Market By Diagnostic Test Type, 2021-2031, USD (Million)
- TABLE 77 Rest of Middle East and Africa Lung Cancer Diagnostics Market By Cancer Type, 2021-2031, USD (Million)
- TABLE 78 Rest of Middle East and Africa Lung Cancer Diagnostics Market By End-User, 2021-2031, USD (Million)
List of Figures
- FIG. 1 Global Lung Cancer Diagnostics Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Lung Cancer Diagnostics Market: Quality Assurance
- FIG. 5 Global Lung Cancer Diagnostics Market, By Diagnostic Test Type, 2022
- FIG. 6 Global Lung Cancer Diagnostics Market, By Cancer Type, 2022
- FIG. 7 Global Lung Cancer Diagnostics Market, By End-User, 2022
- FIG. 8 Global Lung Cancer Diagnostics Market, By Geography, 2022
- FIG. 9 Market Geographical Opportunity Matrix - Global Lung Cancer Diagnostics Market, 2022
FIG. 10Market Positioning of Key Lung Cancer Diagnostics Market Players, 2022
FIG. 11Global Lung Cancer Diagnostics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
- FIG. 12 Global Lung Cancer Diagnostics Market, By Diagnostic Test Type, 2022 Vs 2031, %
- FIG. 13 Global Lung Cancer Diagnostics Market, By Cancer Type, 2022 Vs 2031, %
- FIG. 14 Global Lung Cancer Diagnostics Market, By End-User, 2022 Vs 2031, %
- FIG. 15 U.S. Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 16 Canada Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 17 Rest of North America Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 18 UK Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 19 Germany Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 20 Spain Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 21 Italy Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 22 France Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 23 Rest of Europe Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 24 China Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 25 Japan Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 26 India Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 27 Australia Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 28 South Korea Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 29 Rest of Asia Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 30 Brazil Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 31 Mexico Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 32 Rest of Latin America Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 33 GCC Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 34 Africa Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 35 Rest of Middle East and Africa Lung Cancer Diagnostics Market (US$ Million), 2021 - 2031
